Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.
Location: United States, Massachusetts, Watertown
Member count: 11-50
Total raised: $81M
Founded date: 2019
Funding Rounds 1
Date | Series | Amount | Investors | Deal News |
07.12.2022 | Series A | $81M | - | 4biocapita... |
Mentions in press and media 4
Date | Title | Description | Category | Author | Source |
17.12.2022 | 4BIO Capit... | Company’s proprietary end-to-e... | - | - | 4biocapita... |
07.12.2022 | Entact Bio... | Launch fueled by syndicate of ... | - | - | 4biocapita... |
06.12.2022 | Entact Bio... | Entact Bio, the company pionee... | - | - | brandoncap... |
- | Entact Bio | “Creating new medicines by enh... | - | - | fastfounde... |